Autopsy report · NCT00638378

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

“According to the protocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 11 months before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 3 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Incyte Corporation

Sponsor type

Industry

Conditions

Prostate Cancer

Interventions

Ruxolitinib

Participants

22

Sites

15

Countries

United States

Trials that died the same way

• A 3 Years Naturalistic Cohort Survey of Altis Single Incision Sling System For Female Stress Urinary Incontinence
  “The minimum of enrolled subject defined in the protocol was 180 patients and it was greatly exceeded. Therefore the study was terminated by the sponsor to perform the study analysis.” (67% match in meaning)
• An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
  “As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability.” (67% match in meaning)
• Saracatinib in Treating Patients With Prostate Cancer
  “Per protocol, study was terminated due to low rate of randomized patients.” (66% match in meaning)
• Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
  “After recruitment of Cohorts 1-4 was completed, Sponsor decided to terminate study, initially due to COVID and then considering that PK data from the dose planned to be tested in Cohort 5 (18000 mg) would be available from the ongoing Phase 3 study.” (65% match in meaning)
• A Study of Pertuzumab in Participants With Prostate Cancer
  “The study was terminated at the time of interim analysis since none of the participants showed a PSA response.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.